Volume 11,Issue 2
Celastrol Inhibits Proliferation and Metastatic Potential and Induces Apoptosis in ARID1A-Deficient Non-Small Cell Lung Cancer
Objective: Non-small cell lung cancer (NSCLC) is still challenging to treat due to its high recurrence rate and high metastasis rate. New effective therapeutic drugs urgently need to be developed. Celastrol is a small-molecule compound from traditional Chinese medicine with broad-spectrum anti-tumor activity, but its mechanism of action on ARID1A KO NSCLC has not been fully studied. This study systematically investigated the in vitro antitumor effects of Celastrol on the human NSCLC cell line A549. Methods: The CCK-8 assay was used to assess cell proliferation; wound-healing and Transwell assays evaluated cell migration and invasion, respectively; Annexin V-FITC/PI double staining, combined with flow cytometry, measured cell apoptosis. Results: Celastrol significantly inhibited A549 cell proliferation in a dose- and time-dependent manner, reducing cell viability to approximately 40% at 4 μM after 24 h. The wound-healing and Transwell experiments demonstrated that, compared with the control group, triptolide significantly inhibited cell migration and invasion; flow cytometry showed that the total apoptosis rate of the cells increased significantly after triptolide treatment. Conclusion: Celastrol effectively inhibits A549 cell proliferation, migration, and invasion, and induces apoptosis in a dose-dependent manner. These findings have confirmed the potential of Celastrol as a new candidate drug for the treatment of ARID1A KO NSCLC, and have provided reliable in vitro evidence for subsequent mechanism studies and in vivo research.
[1] Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3): 209–249.
[2] Siegel RL, Miller KD, Wagle NS, et al., 2023, Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1): 17–48.
[3] de Groot PM, Wu CC, Carter BW, et al., 2018, The Epidemiology of Lung Cancer. Translational Lung Cancer Research, 7(3): 220–233.
[4] Meyer ML, Fitzgerald BG, Paz-Ares L, et al., 2024, New Promises and Challenges in the Treatment of Advanced Non-Small-Cell Lung Cancer. The Lancet, 404(10454): 803–822.
[5] Holohan C, Van Schaeybroeck S, Longley DB, et al., 2013, Cancer Drug Resistance: An Evolving Paradigm. Nature Reviews Cancer, 13(10): 714–726.
[6] Herbst RS, Morgensztern D, Boshoff C, 2018, The Biology and Management of Non-Small Cell Lung Cancer. Nature, 553(7689): 446–454.
[7] Chen Z, Fillmore CM, Hammerman PS, et al., 2014, Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases. Nature Reviews Cancer, 14(8): 535–546.
[8] Skoulidis F, Heymach JV, 2019, Co-Occurring Genomic Alterations in Non-Small-Cell Lung Cancer Biology and Therapy. Nature Reviews Cancer, 19(9): 495–509.
[9] Rodak O, Peris-Díaz MD, Olbromski M, et al., 2021, Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers, 13(18): 4705.
[10] Wang X, Haswell JR, Roberts CW, 2014, Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer—Mechanisms and Potential Therapeutic Insights. Clinical Cancer Research, 20(1): 21–27.
[11] Chan TA, Yarchoan M, Jaffee E, et al., 2019, Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology, 30(1): 44–56.
[12] Wiegand KC, Shah SP, Al-Agha OM, et al., 2010, ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. The New England Journal of Medicine, 363(16): 1532–1543.
[13] Athar A, Ahmad E, Bera P, et al., 2025, Molecular Interplay of ARID1A in Gastrointestinal Cancers. Medical Oncology, 42(10): 442.
[14] Hung YP, Redig A, Hornick JL, et al., 2020, ARID1A Mutations and Expression Loss in Non-Small Cell Lung Carcinomas: Clinicopathologic and Molecular Analysis. Modern Pathology, 33(11): 2256–2268.
[15] Wang C, Dai S, Zhao X, et al., 2023, Celastrol as an Emerging Anticancer Agent: Current Status, Challenges and Therapeutic Strategies. Biomedicine & Pharmacotherapy, 163: 114882.
[16] Zhu Y, Meng Y, Zhang J, et al., 2024, Recent Trends in Anti-Tumor Mechanisms and Molecular Targets of Celastrol. International Journal of Biological Sciences, 20(14): 5510–5530.
[17] Kashyap D, Sharma A, Tuli HS, et al., 2018, Molecular Targets of Celastrol in Cancer: Recent Trends and Advancements. Critical Reviews in Oncology/Hematology, 128: 70–81.
[18] Li X, Wang H, Ding J, et al., 2019, Celastrol Strongly Inhibits Proliferation, Migration and Cancer Stem Cell Properties Through Suppression of Pin1 in Ovarian Cancer Cells. European Journal of Pharmacology, 842: 146–156.
[19] Shi J, Li J, Xu Z, et al., 2020, Celastrol: A Review of Useful Strategies Overcoming Its Limitation in Anticancer Application. Frontiers in Pharmacology, 11: 558741.
[20] Lim HY, Ong PS, Wang L, et al., 2021, Celastrol in Cancer Therapy: Recent Developments, Challenges and Prospects. Cancer Letters, 521: 252–267.
[21] Aqil F, Kausar H, Agrawal AK, et al., 2016, Exosomal Formulation Enhances Therapeutic Response of Celastrol Against Lung Cancer. Experimental and Molecular Pathology, 101(1): 12–21.